• venBio Global Strategic Fund IV, L.P., a 10% owner of Attovia Therapeutics, reported a rise in its common stock stake to 4,181,367 shares.
• The increase included 382,352 shares bought at USD 17 per share.
• The filing also reflected additional shares received via conversions of preferred stock into common stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Attovia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000905148-26-003548), on August 10, 2026, and is solely responsible for the information contained therein.